| Business Summary | | Bone
Care
International
Inc.
is
a
pharmaceutical
company
engaged
in
discovering,
developing
and
commercializing
improved
vitamin
D-hormone
therapies
to
treat
secondary
hyperparathyroidism
in
patients
with
kidney,
or
renal
disease,
and
osteoporosis,
and
other
diseases
including
psoriasis
and
cancers
of
the
prostate,
breast
and
colon.
The
Company
licensed
its
first
product,
Hectorol,
in
1987
from
the
University
of
Wisconsin,
a
leading
vitamin
D
research
center.
Hectorol,
also
known
as
doxercalciferol,
is
a
vitamin
D
replacement
therapy
approved
by
the
FDA
in
two
formulations
to
treat
secondary
hyperparathyroidism
in
patients
with
end-stage
renal
disease,
or
ESRD.
In
April
2000,
the
Company
obtained
FDA
approval
for
Hectorol
Injection,
and,
in
late
August
2000,
the
Company
began
selling
this
intravenous
product
in
the
United
States.
The
Company
recently
completed
two
Phase
III
trials
for
Hectorol
Capsules
to
treat
secondary
hyperparathyroidism
in
pre-dialysis
patients. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Bone
Care
International
is
engaged
in
discovering
and
developing
improved
D-hormone
therapies
for
treating
secondary
hyperparathyroidism.
For
the
nine
months
ended
3/31/01,
revenues
totalled
$3.9
million,
up
from
$265
thousand.
Net
loss
fell
3%
to
$6.6
million.
Revenues
benefitted
from
increased
Hectoral
Injection
sales.
Lower
losses
also
benefitted
from
an
increase
in
average
cash
balances
due
to
the
sale
of
common
stock. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,059;
after
tax
earnings
were
-2,374. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Mazess, Ph.D., 61 Chairman,
Acting Pres and CEO | -- | Robert Beckman, 46 CFO,
VP-Fin., Director | -- | Charles Bishop, Ph.D., 49 Exec.
VP, R&D, Director | $152K | Paul Peterson, 49 VP
of Sales and Marketing | 162K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|